초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 08일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제116회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Reliable DB for High-throughput Screening of Therapeutic Antibodies Glycosylation Using LC-MS and LC-MS/MS

2015년 8월 27일 14시 16분 15초
ANAL1.O-24 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
목 10시 : 32분
분석화학 - Oral Presentation of Young Analytical Chemists I
저자 및
윤나영, 서영숙, 안현주*
충남대학교 분석과학기술대학원, Korea
Biosimilar products of monoclonal antibodies (mAbs) are one of the most fast-growing segment of the biotherapeutic market. They commonly have advantages of specificity to targeted antigens and lower safety issues in clinical trials than many other type products. As patents on clinical mAb were beginning to expire, many pharmaceutical companies have been interested in developing for biosimilars. In producing recombinant mAb, glycosylation is considered as a crucial protein quality attribute. Because it is the key factor that can affect to biological activity, as protein stability and immunogenicity, of a therapeutic glycoprotein. Additionally, recombinant antibodies being expressed from non-human mammal cell lines could have the unexpected glycosylation that introduced by host cell’s original glycosylation synthesis. Thus, glycosylation with micro heterogeneity should be screened for modulating protein quality. For identifying the desired/undesired glycosylation, accurate mass was used to compositionally annotate and profile N-glycans while tandem MS using CID was employed for structure elucidation. Here, we created glycoform database for rapid identification and structural elucidation of antibody N-glycosylation based on LC-MS and LC-MS/MS analysis. RT, accurate mass, and diagnostic fragment peak were summed up to identify each glycan. Up to now, glycans from five representative mAbs including adalimumab, bevacizumab, infliximab, rituximab and trastuzumab were analyzed and total 27 glycans were incorporated to database. The glycan DB could be applied with high-throughput glycan characterization method of therapeutic antibodies produced by various cell-based expression systems in pharmaceutical industry.